bioAffinity Technologies, Inc.
For the period ended Dec 31, 2024. Filed Mar 31, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 31, 2025
BIAF$2.26-16.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 11. Executive Compensation
The information required by this item of this Annual Report will be included under the caption “Executive and Director Compensation” in our 2025 Proxy Statement, and is incorporated by reference herein.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.